Literature DB >> 606444

The complications of intravenous Corynebacterium parvum infusion.

P G Gill, P J Morris, M Kettlewell.   

Abstract

100 intravenous infusions of Corynebacterium parvum were given to thirty-six patients at a dose of 5 mg/m2. Fever and rigors occurred in all patients but these acute side effects were acceptable to all but two patients. Seventeen patients suffered a delayed fall in blood pressure, which was marked in eight of them but was generally well tolerated. One patient died 18 hr after infusion from extensive myocardial infarction. Herpes labialis complicated the first infusion in nine instances, which may reflect transient immunosuppression following immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 606444      PMCID: PMC1541127     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  7 in total

1.  Observations following Corynebacterium parvum administration to patients with advanced malignancy. a phase I study.

Authors:  B Fisher; H Rubin; G Sartiano; L Ennis; N Wolmark
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

2.  Tumour growth, phagocytic activity and antibody response in Corynebacterium parvum-treated mice.

Authors:  M F Woodruff; W H McBride; N Dunbar
Journal:  Clin Exp Immunol       Date:  1974-07       Impact factor: 4.330

3.  Depression of delayed hypersensitivity by pretreatment with Freund-type adjuvants. 3. Depressed arrival of lymphoid cells at recently immunized lymph nodes in mice pretreated with adjuvants.

Authors:  G G Allwood; G L Asherson
Journal:  Clin Exp Immunol       Date:  1972-08       Impact factor: 4.330

4.  Biological effects of the adjuvant Corynebacterium parvum. I. Inhibition of PHA, mixed lymphocyte and GVH reactivity.

Authors:  M T Scott
Journal:  Cell Immunol       Date:  1972-11       Impact factor: 4.868

5.  [Corynebacterium parvum in advanced cancers. 1st evaluation of the therapeutic activity of this immunostimulin].

Authors:  L Israël; B Halpern
Journal:  Nouv Presse Med       Date:  1972-01-01

6.  Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: a preliminary report of clinical and biologic findings.

Authors:  L Israël; R Edelstein; A Depierre; N Dimitrov
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

7.  Nonspecific immunotherapy by Corynebacterium parvum: phase I toxicity study in 12 patients with advanced cancer.

Authors:  V S Cheng; H D Suit; C C Wang; C Cummings
Journal:  Cancer       Date:  1976-04       Impact factor: 6.860

  7 in total
  2 in total

1.  Effect of intravenous corynebacterium parvum on peripheral-blood effector cells of cancer patients.

Authors:  P G Gill; C A Waller; I C MacClennan; P J Morris
Journal:  Br J Cancer       Date:  1980-05       Impact factor: 7.640

2.  A trial of nonspecific immunotherapy using systemic C. parvum in treated patients with Dukes B and C colorectal cancer.

Authors:  R G Souter; P G Gill; P J Morris
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.